Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

医学 血管性血友病因子 ADAMTS13号 胃肠病学 血栓性血小板减少性紫癜 血小板 内科学 安慰剂 外科 免疫学 病理 替代医学
作者
Marie Scully,Spero R. Cataland,Flora Peyvandi,Paul Coppo,Paul Knöbl,Johanna A. Kremer Hovinga,Ara D. Metjian,Javier de la Rubia,Katerina Pavenski,Filip Callewaert,Debjit Biswas,Hilde A.M. De Winter,Robert K. Zeldin
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:380 (4): 335-346 被引量:1097
标识
DOI:10.1056/nejmoa1806311
摘要

BACKGROUND: In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor-cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia. Caplacizumab, an anti-von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, inhibits interaction between von Willebrand factor multimers and platelets. METHODS: In this double-blind, controlled trial, we randomly assigned 145 patients with TTP to receive caplacizumab (10-mg intravenous loading bolus, followed by 10 mg daily subcutaneously) or placebo during plasma exchange and for 30 days thereafter. The primary outcome was the time to normalization of the platelet count, with discontinuation of daily plasma exchange within 5 days thereafter. Key secondary outcomes included a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the trial treatment period; recurrence of TTP at any time during the trial; refractory TTP; and normalization of organ-damage markers. RESULTS: The median time to normalization of the platelet count was shorter with caplacizumab than with placebo (2.69 days [95% confidence interval {CI}, 1.89 to 2.83] vs. 2.88 days [95% CI, 2.68 to 3.56], P=0.01), and patients who received caplacizumab were 1.55 times as likely to have a normalization of the platelet count as those who received placebo. The percentage of patients with a composite outcome event was 74% lower with caplacizumab than with placebo (12% vs. 49%, P<0.001). The percentage of patients who had a recurrence of TTP at any time during the trial was 67% lower with caplacizumab than with placebo (12% vs. 38%, P<0.001). Refractory disease developed in no patients in the caplacizumab group and in three patients in the placebo group. Patients who received caplacizumab needed less plasma exchange and had a shorter hospitalization than those who received placebo. The most common adverse event was mucocutaneous bleeding, which was reported in 65% of the patients in the caplacizumab group and in 48% in the placebo group. During the trial treatment period, three patients in the placebo group died. One patient in the caplacizumab group died from cerebral ischemia after the end of the treatment period. CONCLUSIONS: Among patients with TTP, treatment with caplacizumab was associated with faster normalization of the platelet count; a lower incidence of a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the treatment period; and a lower rate of recurrence of TTP during the trial than placebo. (Funded by Ablynx; HERCULES ClinicalTrials.gov number, NCT02553317 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
晓宇发布了新的文献求助10
1秒前
郑睿涛发布了新的文献求助10
1秒前
2秒前
2秒前
2秒前
jing发布了新的文献求助10
3秒前
3秒前
3419549959完成签到,获得积分10
4秒前
4秒前
4秒前
AAA发布了新的文献求助10
5秒前
5秒前
香蕉觅云的应助被特仑苏采纳,获得10
6秒前
爱吃秋刀鱼的大脸猫完成签到,获得积分10
6秒前
NiNi发布了新的文献求助10
7秒前
黑米粥发布了新的文献求助200
8秒前
8秒前
9秒前
桃子汽水发布了新的文献求助10
9秒前
苏小满关注了科研通微信公众号
10秒前
彭泽阳完成签到,获得积分10
10秒前
干就完发布了新的文献求助10
10秒前
10秒前
不开花花发布了新的文献求助10
11秒前
11秒前
李元发布了新的文献求助10
12秒前
12秒前
13秒前
13秒前
14秒前
14秒前
14秒前
Even完成签到,获得积分10
14秒前
Seorina发布了新的文献求助20
14秒前
14秒前
15秒前
15秒前
15秒前
领导范儿的应助被xiaoqiao采纳,获得30
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183880
求助须知:如何正确求助?哪些是违规求助? 9573054
关于积分的说明 21828982
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434134
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480634